Search Results 991-1000 of 16352 for monoclonal antibody

1. Cyclophosphamide and Vaccine Therapy in Treating Patients with Stage II-III Breast, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer - Mayo Clinic

   ... monoclonal antibodies, small molecule inhibitors) for this cancer; Known history of autoimmune disease; Any contraindication to receiving sargramostim (GM-CSF) ...

2. A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) - Mayo Clinic

   Receipt of an investigational immunomodulator or monoclonal antibody within 180 days (or 5 half-lives, whichever is longer) prior to Screening. Receipt of ...

3. Publications - Aaron R. Mangold, M.D. - Mayo Clinic

   The evolving understanding of risk with calcitonin gene-related peptide monoclonal antibodies based on real-world data: A focus on hypertension and Raynaud ...

4. A Study of Pembrolizumab Alone as Therapy for Metastatic Triple-Negative Breast Cancer - Mayo Clinic

   Prior anti-cancer monoclonal antibody (mAb) therapy for direct anti-neoplastic treatment within 4 weeks prior to study Day 1; Prior chemotherapy, targeted ...

5. A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) - Mayo Clinic

   Any prior systemic chemotherapy, small molecule inhibitors, immune checkpoint inhibitors, other monoclonal antibodies, antibody-drug conjugates ...

6. Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy - Mayo Clinic

   Patients who have been treated with at least 1 dose of alirocumab or any other anti-PCSK9 monoclonal antibody in any other clinical studies; Pregnant or ...

7. Publications - Madiha Fida, M.B.B.S. - Mayo Clinic

   ... monoclonal antibody escape mutation in a persistently infected, immunocompromised individual. Virus Evol. 2023; 9 (2):veac104 Epub 2022 Nov 05. View PubMed ...

8. CSF1R and TAM receptor inhibition with Q702 - Mayo Clinic

   Participation eligibility · Targeted therapeutics other than monoclonal antibodies (e.g., kinases inhibitors) ≤2 weeks prior to registration. · Monoclonal ...

9. A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma - Mayo Clinic

   History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products.

10. A Study to Evaluate Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer - Mayo Clinic

    Within 4 weeks (28 days): systemic cytotoxic chemotherapy; small molecule targeted agents with half-life ≥ 7 days; monoclonal antibodies, antibody-drug ...